- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07739550
Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women
Therapeutic Effects of Low-Intensity Extracorporeal Shock Wave Therapy on Refractory Overactive Bladder Symptoms in Females
Overactive bladder is a condition characterized by a sudden and difficult-to-control need to urinate, which may occur with frequent urination, nighttime urination, and urine leakage. Some women continue to experience these symptoms despite lifestyle changes, behavioral therapy, and medication, or they cannot tolerate or decline medical treatment.
This study will evaluate whether low-intensity extracorporeal shock wave therapy (Li-ESWT), a non-surgical treatment delivered externally over the lower abdomen, can safely improve refractory overactive bladder symptoms in women.
A total of 40 women will be randomly assigned in equal numbers to receive either active Li-ESWT or a sham treatment. Both groups will attend one treatment session each week for six weeks. The sham procedure will be similar to the active treatment in positioning, session duration, and device sound but will not deliver shock wave energy.
Symptoms will be assessed using the validated Arabic version of the 8-item Overactive Bladder Questionnaire (OAB-V8) before treatment and during follow-up. The main purpose of the study is to compare the change in OAB-V8 symptom score between the two groups after one month. Additional assessments at three months will include post-void residual urine volume, information from a 3-day voiding diary, the participant's overall impression of improvement, and any treatment-related adverse events.
The study hypothesis is that Li-ESWT will improve overactive bladder symptoms and quality of life compared with sham treatment.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Abdelrahman F Senosy, MBBCh
- Numéro de téléphone: +02 010 95324741
- E-mail: Abdelrahmanadam96@gmail.com
Lieux d'étude
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypte, 11511
- Ain Shams University Hospital
-
Contact:
- Abdelrahman F Senosy, MBBCh
- Numéro de téléphone: +2 010 95324741
- E-mail: Abdelrahmanadam96@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Female participants aged 18 to 70 years.
- Symptoms of overactive bladder with an Overactive Bladder Questionnaire 8-Item total score greater than 8.
- Failure of behavioral therapy and medical treatment for overactive bladder.
- Refusal of medical treatment for overactive bladder. Ability to understand the study procedures and provide written informed consent.
Exclusion Criteria:
- Current use of medical treatment for overactive bladder.
- Cardiac pacemaker or metallic implant in the treatment area.
- Coagulation disorder or use of anticoagulants that cannot be temporarily discontinued.
- Active urinary tract infection; participants may be reconsidered after successful treatment and recovery.
- Urinary bladder stones.
- Post-void residual urine volume greater than 100 mL.
- Lower urinary tract surgery within the previous 6 months.
- Previous pelvic radiation therapy.
- History of neuropathic disease.
- Pregnancy or planning to become pregnant.
- Hepatic, renal, or cardiac impairment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Active Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive active low-intensity extracorporeal shock wave therapy using the PiezoWave 2 focused extracorporeal shock wave therapy device.
Treatment will be administered once weekly for 6 weeks.
Before each session, participants will drink 1000 mL of water, and treatment will begin when the bladder reaches approximately 50% of the participant's functional bladder capacity, confirmed by bladder scan.
The probe will be placed over the lower abdomen approximately two fingerbreadths above the pubic symphysis and directed toward the bladder dome and bilateral bladder walls.
Each session will deliver 1000 impulses to each target area, for a total of 3000 impulses, at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second.
|
Focused low-intensity extracorporeal shock wave therapy will be delivered using the PiezoWave 2 device.
Each session will deliver a total of 3000 impulses at an energy density of 0.25 mJ/mm² and a frequency of 3 pulses per second.
Treatment will be administered once weekly for 6 weeks.
|
|
Comparateur factice: Sham Low-Intensity Extracorporeal Shock Wave Therapy
Participants will receive a sham procedure once weekly for 6 weeks.
The procedure will be similar to the active treatment in participant positioning, bladder preparation, probe placement, session duration, and device sound.
A sham probe or zero-energy device setting will be used so that no therapeutic shock wave energy is delivered.
|
A sham procedure will be administered using the same treatment setup, participant positioning, probe placement, session duration, and device sound as active therapy.
A sham probe or zero-energy setting will be used so that no therapeutic shock wave energy is delivered.
The procedure will be performed once weekly for 6 weeks.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overactive Bladder Questionnaire 8-Item Total Score
Délai: Baseline and 1 month after completion of the 6-week treatment
|
The Arabic-validated Overactive Bladder Questionnaire 8-Item (OAB-V8) will be completed at baseline and 1 month after completion of treatment.
The questionnaire contains 8 items scored from 0 to 5, giving a total score ranging from 0 to 40.
Higher scores indicate greater symptom-related bother.
The outcome will be calculated as the change in total OAB-V8 score from baseline to the 1-month assessment.
|
Baseline and 1 month after completion of the 6-week treatment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Post-Void Residual Urine Volume at 3 Months
Délai: Baseline and 3 months after completion of treatment
|
Post-void residual urine volume will be measured by ultrasound after urination and recorded in milliliters.
The outcome will be calculated as the change from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Urinary Frequency Recorded in a 3-Day Voiding Diary
Délai: Baseline and 3 months after completion of treatment
|
Participants will record the timing and number of urination episodes in a 3-day voiding diary.
The outcome will assess the change in urinary frequency from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Mean Voided Urine Volume Recorded in a 3-Day Voiding Diary
Délai: Baseline and 3 months after completion of treatment
|
The volume of urine passed during each urination will be recorded in milliliters in a 3-day voiding diary.
Mean voided volume will be calculated, and the change from baseline to the 3-month follow-up assessment will be evaluated.
|
Baseline and 3 months after completion of treatment
|
|
Urgency Level Recorded in a 3-Day Voiding Diary
Délai: Baseline and 3 months after completion of treatment
|
Participants will record the level of urinary urgency associated with each urination episode in a 3-day voiding diary.
The outcome will assess the change in recorded urgency level from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Urinary Leakage Episodes Recorded in a 3-Day Voiding Diary
Délai: Baseline and 3 months after completion of treatment
|
The number of involuntary urinary leakage episodes will be recorded over 3 consecutive days.
The outcome will be calculated as the change in the number of leakage episodes from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
|
Functional Bladder Capacity
Délai: Baseline and 3 months after completion of treatment
|
Functional bladder capacity will be derived from measurements recorded in the participant's 3-day voiding diary and expressed in milliliters.
The outcome will assess the change from baseline to the 3-month follow-up assessment.
|
Baseline and 3 months after completion of treatment
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Incontinence urinaire d'urgence
- Nycturie
- Urgence urinaire
- Fréquence urinaire
- Thérapie extracorporelle par ondes de choc de faible intensité
- Vessie hyperactive réfractaire
- Female Lower Urinary Tract Symptoms
- Functional Bladder Capacity
- Post-Void Residual Urine
- Sham-Controlled Clinical Trial
- Overactive Bladder Questionnaire, 8-Item
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies urogénitales masculines
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Symptômes des voies urinaires inférieures
- Manifestations urologiques
- Maladies de la vessie urinaire
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Vessie urinaire, hyperactive
- Nycturie
Autres numéros d'identification d'étude
- FMASU MS 434/2026
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .